CoChat

Brewpitopes: a pipeline to refine B-cell epitope predictions during public health emergencies

Open access
Farriol-Duran, Roc, López-Aladid, Ruben, Porta-Pardo, Eduard, Torres, Antoni, Fernández-Barat, Laia · 2022 · Frontiers in Immunology

Preprint — published as 10.3389/fimmu.2023.1278534

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

The application of B-cell epitope identification for the development of therapeutic antibodies is well established but consuming in terms of time and resources. For this reason, in the last few years, the immunoinformatic community has developed several computational predictive tools. While relatively successful, most of these tools only use a few properties of the candidate region to determine their likelihood of being a true B-cell epitope. However, this likelihood is influenced by a wide variety of protein features, including the presence of glycosylated residues in the neighbourhood of the candidate epitope, the subcellular location of the protein region or the three-dimensional information about their surface accessibility in the parental protein. In this study we created Brewpitopes, an integrative pipeline to curate computational predictions of B-cell epitopes by accounting for all the aforementioned features. To this end, we implemented a set of rational filters to mimic the conditions for the in vivo antibody recognition to enrich the B-cell epitope predictions in actionable candidates. To validate Brewpitopes, we analyzed the SARS-CoV-2 proteome. In the S protein, Brewpitopes enriched the initial predictions in 5-fold on epitopes with neutralizing potential (p-value < 2e-4). Other than S protein, 4 out of 16 proteins in the proteome contain curated B-cell epitopes and hence, have also potential interest for viral neutralization, since mutational escape mainly affects the S protein. Our results demonstrate that Brewpitopes is a powerful pipeline for the rapid prediction of refined B-cell epitopes during public health emergencies. Statement of significance: We have created Brewpitopes, a new pipeline that integrates additional important features such as glycosylation or structural accessibility, to curate B-cell epitope more likely to be functional in vivo. We have also validated Brewpitopes against SARS-CoV-2 not only for S protein but also for the entire viral proteome demonstrating that is a rapid and reliable epitope predictive tool to be implemented in present or future public health emergencies. Brewpitopes has identified 7 SARS-CoV-2 epitopes in S and epitopes allocated in 4 other proteins. Overall, offering an accurate selection of epitopes that might be scaled up to the production of new antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.11.28.518301

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Biophysical constraints for in vivo antibody recognition. (A) Recognition of extracellular or extra-viral protein regions. Neutralizing antibodies only inspect the external surface of viral particles. Therefore, predicted epitopes located in intracellular or transmembrane epitopes will not be recognized. In Brewpitopes, we used protein topology-annotated information and topology predictors to assess the subcellular location of the target protein regions with predicted epitopes. Exclusively, candidates located on extracellular protein regions were selected. (B) Glycosylation coverage prevents in vivo antibody recognition of neutralizing epitopes. Predicted epitopes that contain glycosylation motifs are likely covered by glycans supporting the selection of predicted epitopes without glycosylated residues. In Brewpitopes, we predicted the glycosylation profiles of target proteins using Net-N-glyc and Net-O-glyc for N- and O-glycosylations, respectively. Only predicted epitopes without glycosylated residues pass this filter. (C) Epitope accessibility on parental protein surface. Predicted epitopes that contain buried residues will be less accessible for in vivo antibody recognition. Left: structure of S protein of SARS-CoV-2 highlighting a fully accessible predicted epitope. Right: structure of the S protein displaying a highly buried predicted epitope. In Brewpitopes, to assess epitope accessibility, we calculated the Residue Solvent Accessibility (RSA) of the predicted epitope sequences using crystal or structural models. Once predicted, fully accessible epitopes (all residues RSA ≥ 0.2) were selected and buried candidates were discarded (at least one residue RSA < 0.2).
Figure 1 Biophysical constraints for in vivo antibody recognition. (A) Recognition of extracellular or extra-viral protein regions. Neutralizing antibodies only inspect the external surface of viral particles. Therefore, predicted epitopes located in intracellular or transmembrane epitopes will not be recognized. In Brewpitopes, we used protein topology-annotated information and topology predictors to assess the subcellular location of the target protein regions with predicted epitopes. Exclusively, candidates located on extracellular protein regions were selected. (B) Glycosylation coverage prevents in vivo antibody recognition of neutralizing epitopes. Predicted epitopes that contain glycosylation motifs are likely covered by glycans supporting the selection of predicted epitopes without glycosylated residues. In Brewpitopes, we predicted the glycosylation profiles of target proteins using Net-N-glyc and Net-O-glyc for N- and O-glycosylations, respectively. Only predicted epitopes without glycosylated residues pass this filter. (C) Epitope accessibility on parental protein surface. Predicted epitopes that contain buried residues will be less accessible for in vivo antibody recognition. Left: structure of S protein of SARS-CoV-2 highlighting a fully accessible predicted epitope. Right: structure of the S protein displaying a highly buried predicted epitope. In Brewpitopes, to assess epitope accessibility, we calculated the Residue Solvent Accessibility (RSA) of the predicted epitope sequences using crystal or structural models. Once predicted, fully accessible epitopes (all residues RSA ≥ 0.2) were selected and buried candidates were discarded (at least one residue RSA < 0.2).CC BY · PubMed Central
Figure 2 Brewpitopes pipeline. Linear and conformational epitope predictions are performed using Bepipred2.0, ABCpred, and Discotope2.0. Epitope extraction is customized in each tool’s output using Epixtractor. Extracted epitopes are standardized using Epimerger. Subsequently, Brewpitopes implements three in silico predictors of biophysical constraints for in vivo antibody recognition: subcellular location, glycosylation coverage, and surface accessibility. Protein topology information to determine subcellular location can be uploaded into Brewpitopes using annotated data or via CCTOP predictions (.xml output) using Epitopology. Predicted epitopes located in extracellular regions are selected. Intracellular and transmembrane epitopes are discarded. Glycosylation patterns of target proteins are predicted with Net-N-Glyc and Net-O-Glyc and the output is used by Epiglycan to label all predicted epitopes containing one glycosylated residue as “glycosylated” and candidates not containing glycosylated positions as “non-glycosylated”. Epitope accessibility on the 3D surface of the parental protein structure is computed via compute_asa.icm (Molsoft - ICM Browser) and a PDB file obtained from a crystal structure or a computational model. Predicted RSA values are used by Epiaccess to label fully accessible epitopes as “accessible” (all residues RSA ≥ 0.2) and candidates containing at least one buried residue as “buried” (RSA < 0.2). The filtering of the candidate epitopes according to the predicted biophysical constraints (labeled as “extracellular”, “non-glycosylated”, and “accessible”) is performed by Epifilter. Curated candidates predicted by different tools will result in overlapping epitopes that are merged into epitope regions using Epiconsensus.
Figure 2 Brewpitopes pipeline. Linear and conformational epitope predictions are performed using Bepipred2.0, ABCpred, and Discotope2.0. Epitope extraction is customized in each tool’s output using Epixtractor. Extracted epitopes are standardized using Epimerger. Subsequently, Brewpitopes implements three in silico predictors of biophysical constraints for in vivo antibody recognition: subcellular location, glycosylation coverage, and surface accessibility. Protein topology information to determine subcellular location can be uploaded into Brewpitopes using annotated data or via CCTOP predictions (.xml output) using Epitopology. Predicted epitopes located in extracellular regions are selected. Intracellular and transmembrane epitopes are discarded. Glycosylation patterns of target proteins are predicted with Net-N-Glyc and Net-O-Glyc and the output is used by Epiglycan to label all predicted epitopes containing one glycosylated residue as “glycosylated” and candidates not containing glycosylated positions as “non-glycosylated”. Epitope accessibility on the 3D surface of the parental protein structure is computed via compute_asa.icm (Molsoft - ICM Browser) and a PDB file obtained from a crystal structure or a computational model. Predicted RSA values are used by Epiaccess to label fully accessible epitopes as “accessible” (all residues RSA ≥ 0.2) and candidates containing at least one buried residue as “buried” (RSA < 0.2). The filtering of the candidate epitopes according to the predicted biophysical constraints (labeled as “extracellular”, “non-glycosylated”, and “accessible”) is performed by Epifilter. Curated candidates predicted by different tools will result in overlapping epitopes that are merged into epitope regions using Epiconsensus.CC BY · PubMed Central
Figure 3 Epitope refinement for SARS-CoV-2 Wuhan S protein. The x-axis represents the filtering steps of the pipeline. The y-axis displays the number of epitopes refined by each filtering step of Brewpitopes.
Figure 3 Epitope refinement for SARS-CoV-2 Wuhan S protein. The x-axis represents the filtering steps of the pipeline. The y-axis displays the number of epitopes refined by each filtering step of Brewpitopes.CC BY · PubMed Central
Figure 4 Visualization of predicted epitope location on the 3D structure of SARS-CoV-2 S protein to compare the initially predicted epitopes versus the epitopes refined by Brewpitopes. This representation depicts the shrinkage of the region to be explored and experimentally validated since unrefined predictions represent a much larger surface than the epitopes refined by Brewpitopes. Left: Front view of the S protein 3D structure. Right: Top view. All the epitopes were only labeled on the chain A of the S protein for visualization purposes (blue). The epitope regions 6 and 7 were not displayed because they escaped the limits of the represented structure. Owing to the large number candidates predicted by ABCpred, only the best scored candidates of this software were included in the 3D representation.
Figure 4 Visualization of predicted epitope location on the 3D structure of SARS-CoV-2 S protein to compare the initially predicted epitopes versus the epitopes refined by Brewpitopes. This representation depicts the shrinkage of the region to be explored and experimentally validated since unrefined predictions represent a much larger surface than the epitopes refined by Brewpitopes. Left: Front view of the S protein 3D structure. Right: Top view. All the epitopes were only labeled on the chain A of the S protein for visualization purposes (blue). The epitope regions 6 and 7 were not displayed because they escaped the limits of the represented structure. Owing to the large number candidates predicted by ABCpred, only the best scored candidates of this software were included in the 3D representation.CC BY · PubMed Central
Figure 5 Epitope refinement for the S protein of the Omicron variant. The x-axis represents the steps of the Brewpitopes pipeline and the y-axis denotes the number of epitopes selected by each filtering step of Brewpitopes ( Figure 2 ). Omicron’s epitope yield obtained with Brewpitopes (six epitope regions) is lower than Wuhan WT’s yield (seven epitope regions).
Figure 5 Epitope refinement for the S protein of the Omicron variant. The x-axis represents the steps of the Brewpitopes pipeline and the y-axis denotes the number of epitopes selected by each filtering step of Brewpitopes ( Figure 2 ). Omicron’s epitope yield obtained with Brewpitopes (six epitope regions) is lower than Wuhan WT’s yield (seven epitope regions).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 7

  1. 2017, The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design, Front. Immunol, 8, 278
  2. 2020, in Methods in Molecular Biology, 2131, 299
  3. 10.1093/bioinformatics/xxxxxx · doi:10.1093/bioinformatics/xxxxxx
  4. 2016, Comparative Protein Structure Modeling Using MODELLER, Curr. Protoc. Bioinforma, 54, 5
  5. 2021, Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), BMC Immunol, 22, 1
  6. 2021, Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data, Front. Artif. Intell, 0, 31
  7. 10.1016/J.IMMUNI.2021.08.016/ATTACHMENT/7E46D867-B6BF4AD1-9225-0910A493D882/MMC1.PDF · doi:10.1016/j.immuni.2021.08.016/attachment/7e46d867-b6bf4ad1-9225-0910a493d882/mmc1.pdf

Metadata

Authors
Farriol-Duran, R., López-Aladid, R., Porta-Pardo, E., Torres, A., & Fernández-Barat, L.
Affiliations
Barcelona Supercomputing Center (ES)
Venue
Frontiers in Immunology
Publisher
openRxiv
Published
2022-11-29
Volume
14
Pages
1278534-1278534
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4389393290
Cited by
4
References
45
Citations by year
2026: 2 · 2025: 2
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UPCommons institutional repository (Universitat Politècnica de Catalunya) (submittedVersion, cc-by-nc-nd)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Instituto de Salud Carlos III
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
B-cell epitope prediction, SARS-CoV-2, S protein, variants of concern, immune evasion, neutralizing epitopes, glycosylation, surface accessibility, therapeutic antibodies, vaccine candidate, public health emergencies
MeSH terms
SARS-CoV-2, Emergencies, Humans, Public Health, Viral Vaccines, Epitopes, T-Lymphocyte, Epitopes, B-Lymphocyte

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brewpitopes: a pipeline to refine B-cell epitope predictions during public health emergencies. https://app.cochat.ai/papers/10.1101/2022.11.28.518301
The paper
Farriol-Duran, R., López-Aladid, R., Porta-Pardo, E., Torres, A., & Fernández-Barat, L. (2022). Brewpitopes: a pipeline to refine B-cell epitope predictions during public health emergencies. Frontiers in Immunology. https://doi.org/10.1101/2022.11.28.518301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.